Ipamorelin vs sermorelin: which one for sleep, and why the cleanest stack is both

Ipamorelin and sermorelin are the two growth hormone secretagogues that come up most often in conversations about sleep, recovery, and healthy ageing. They are not the same peptide, they do not work the same way, and the head-to-head has a more interesting answer than 'one is better'.

Two different mechanisms

Sermorelin is a GHRH analogue. It mimics the body's natural growth hormone-releasing hormone and acts on the GHRH receptor in the pituitary. The result is a slow, steady amplification of the body's own growth hormone pulse, with the timing tied to the natural circadian rhythm of GH release.

Ipamorelin is a selective ghrelin-receptor agonist. It mimics ghrelin (the hunger hormone) at the growth hormone secretagogue receptor. The result is a sharp, fast-onset growth hormone pulse with minimal cortisol or prolactin co-release. Ipamorelin is the cleanest of the GHRPs on those co-release markers.

Both are physiologically pulsed rather than continuously elevated. That is the point. Continuous exogenous growth hormone suppresses endogenous production. Pulsed secretagogue stimulation does not.

Sleep is the headline

Both peptides improve sleep architecture, with the mechanism running through increased GH release during slow-wave sleep. Huberman has publicly discussed using sermorelin 3 to 5 nights per week before bed. The sleep improvements typically show up in the first 1 to 4 weeks.

Sermorelin's evidence base for sleep-specific effects is stronger. Steiger et al. demonstrated that GHRH administration promotes slow-wave sleep (the deepest, most restorative sleep phase) and enhances nocturnal GH secretion. Sermorelin, as a GHRH analogue, gets the same effect when dosed at bedtime.

Ipamorelin's sleep effect is similar in direction but can be more noticeable early in a protocol. The absence of cortisol elevation is the key advantage: elevated cortisol is directly antagonistic to deep sleep. For a person with early sleep disruption or cortisol sensitivity, ipamorelin's selectivity gives it a practical edge.

Dosing

Ipamorelin: 100 to 300 micrograms per injection, capped at 100 micrograms per single dose by Koniver's published rule. Higher doses (200 to 400 micrograms) can produce flushing, headaches, and rarely anaphylactoid reactions. Injected at bedtime on an empty stomach, with no carbohydrate in the prior 45 to 60 minutes. 5 nights on, 2 off, in 12-week blocks with 4 weeks off to prevent receptor desensitisation.

Sermorelin: 200 micrograms at the low end for sleep, up to 1,000 to 3,000 micrograms per day for higher GH effect. Koniver and Huberman both note a wide working range. 5 days on, 2 days off, or daily 5 days a week with weekend breaks.

The cleanest stack

Most longevity clinics that work with both peptides use them together rather than asking patients to choose. The CJC-1295 (no DAC) + ipamorelin stack is the most common practitioner pattern: 100 to 300 micrograms each, both at bedtime, 5 nights on and 2 off.

The reason is that CJC-1295 (no DAC) is a GHRH analogue with a 30-minute half-life, which produces a sharp, single pulse. Adding ipamorelin (a ghrelin mimetic) produces a full physiological GH wave: a GHRH-driven pulse from CJC-1295, amplified by a ghrelin-receptor pulse from ipamorelin. The combination mimics what the body does naturally during deep sleep.

Sermorelin still has a role. For a patient who does not tolerate ipamorelin, or who is starting with a single peptide and wants the simplest path, sermorelin monotherapy is reasonable.

What the head-to-head data shows

No published randomised controlled trial has evaluated ipamorelin for body composition, bone density, or anti-ageing endpoints in adults. No randomised trial has ever compared sermorelin directly against ipamorelin in the same patient cohort. Any claim of superiority for one peptide over the other is inference, not evidence.

The practical difference for most patients comes down to tolerability (flushing and injection-site reactions favour ipamorelin) and the prescriber's comfort with the available evidence base (which favours sermorelin). Neither peptide has the phase III efficacy data that would satisfy evidence-based medicine standards for adult anti-ageing applications.

Who should pick which

If the primary goal is sleep improvement and you want the simplest single-peptide path with the longest clinical track record, sermorelin. If the primary goal is sleep plus body composition plus recovery, and you tolerate bedtime injection on an empty stomach, ipamorelin or the CJC-1295 + ipamorelin stack.